Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Department of Management Science and Engineering, Stanford University, Stanford, CA 94305, USA.
Cell Rep Med. 2021 Apr 20;2(4):100245. doi: 10.1016/j.xcrm.2021.100245. Epub 2021 Mar 23.
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and variants has led to significant mortality. We recently reported that an RNA-targeting CRISPR-Cas13 system, called prophylactic antiviral CRISPR in human cells (PAC-MAN), offered an antiviral strategy against SARS-CoV-2 and influenza A virus. Here, we expand analysis to use PAC-MAN to target a broad spectrum of human- or livestock-infectious RNA viruses with high specificity, coverage, and predicted efficiency. Our analysis reveals that a minimal set of 14 CRISPR RNAs (crRNAs) is able to target >90% of human-infectious viruses across 10 RNA virus families. We predict that a set of 5 experimentally validated crRNAs can target new SARS-CoV-2 variant sequences with zero mismatches. We also build an online resource (crispr-pacman.stanford.edu) to support community use of CRISPR-Cas13 for broad-spectrum RNA virus targeting. Our work provides a new bioinformatic resource for using CRISPR-Cas13 to target diverse RNA viruses to facilitate the development of CRISPR-based antivirals.
由严重急性呼吸系统综合症冠状病毒 2 型(SARS-CoV-2)和其变体引起的 2019 年冠状病毒病(COVID-19)大流行导致了大量死亡。我们最近报道称,一种称为人类细胞中预防性抗病毒 CRISPR(PAC-MAN)的靶向 RNA 的 CRISPR-Cas13 系统为对抗 SARS-CoV-2 和甲型流感病毒提供了一种抗病毒策略。在这里,我们将分析扩展到使用 PAC-MAN 以高特异性、覆盖率和预测效率靶向广泛的人类或牲畜感染性 RNA 病毒。我们的分析表明,一组 14 种最小的 CRISPR RNA(crRNA)能够靶向超过 10 种 RNA 病毒家族中 90%以上的人类感染性病毒。我们预测,一组 5 种经过实验验证的 crRNA 可以靶向新的 SARS-CoV-2 变体序列,完全没有错配。我们还构建了一个在线资源(crispr-pacman.stanford.edu),以支持社区使用 CRISPR-Cas13 对广谱 RNA 病毒进行靶向。我们的工作为使用 CRISPR-Cas13 靶向不同的 RNA 病毒提供了一个新的生物信息学资源,以促进基于 CRISPR 的抗病毒药物的开发。